HealthdirectFree Australian health advice you can count on.

• Women of childbearing age should take an effective contraceptive measure during the treatment with encorafenib and continue taking contraceptives for at least two weeks after the last dose of encorafenib. • Breastfeeding mothers should not breastfeed their children during encorafenib treatment and for at least two weeks from the last dose. • A pregnancy test should be done on women of childbearing age before the therapy, and the treatment with encorafenib should be started only if the pregnancy test reads negative. • Men of reproductive potential shoul‍‍‍‍‍‍​​​‍​​​​​​d plan to store their sperms in a sperm bank before starting encorafenib treatment as it may affect their fertility status. • Patients should be monitored for any abnormalities in heart rhythm and dose with encorafenib can be reduced, or treatment may be discontinued if the rhythm has a prolongation greater than 500 milliseconds. • Look for any electrolyte abnormalities during the treatment with encorafenib and correct if any low levels of potassium or magnesium occur. • Skin examination should be performed before starting treatment with encorafenib that should be followed up every two months during the treatment and six months after stopping the encorafenib treatment. • Eye disorders including new or worsening of visual disturbances can occur with encorafenib treatment; therefore patients should be advised to meet an eye specialist and to check their eye function at regular intervals. • Bleeding events can occur during treatment with encorafenib and binimetinib combination. The most common is bleeding in the stomach and worsening of bleeding in hemorrhoids or piles which require treatment modification.